Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis

Table 4 Secondary safety outcomes

	ARNI (N = 87)	Standard treatment (N = 100)	p-value
Mean changes of key laboratories and vital signs
Systolic blood pressure (mmHg)	+ 0.55 ± 16.3	+ 2.88 ± 18.1	0.355
Diastolic blood pressure (mmHg)	-0.24 ± 9.4	-0.50 ± 11.2	0.864
Serum sodium (mEq/L)	+ 0.54 ± 3.0	+ 0.20 ± 3.6	0.655
Serum potassium (mEq/L)	+ 0.17 ± 0.5	+ 0.22 ± 0.8	0.612
Serum creatinine (mg/dL)*	+ 0.04 (0.28)	+ 0.14 (0.56)	< 0.001
Clinical signs and symptoms for safety outcomes (%)
Dry cough	7 (8.0)	11 (11.0)	0.062
Angioedema	0	0	–
Hypotension**	12 (13.8)	5 (5.0)	0.043
Symptomatic orthostatic hypotension***	22 (25.3)	13 (13.0)	0.032
Asymptomatic orthostatic hypotension***	18 (20.7)	11 (11.0)	0.068

ARNI = angiotensin receptor/ neprilysin inhibitor
^*Reported as median (interquartile range)
^**Fisher Exact test
^***Orthostatic hypotension: a physical finding defined by the American Autonomic Society and the American Academy of Neurology as a systolic blood pressure decrease of at least 20 mm Hg or a diastolic blood pressure decrease of at least 10 mm Hg within three minutes of standing

ISSN: 1471-2261